ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1302 • 2013 ACR/ARHP Annual Meeting

    Application of Cytostatic Agent Kinesin Eg5 Inhibitor Litronesib (KF89617) On Rat Adjuvant-Induced Arthritis and Mouse Type II Collagen-Induced Arthritis

    Ichiro Miki1 and Masako Uchii2, 1Fuji Research Park, Kyowa Hakko Kirin, Co., Ltd., Shizuoka, Japan, 2Fuji Research Park, Kyowa Hakko Kirin Co., Ltd., Shizuoka, Japan

    Background/Purpose:   Kinesins are family of motor proteins that are involved in mitosis and intracellular transport of vesicles and organelles. The mitotic kinesin, Eg5, acts…
  • Abstract Number: 1315 • 2013 ACR/ARHP Annual Meeting

    14-3-3η and Its Auto-Antibodies Predict Response To Anti-TNF Therapy

    Walter P. Maksymowych1 and Anthony Marotta2, 1Medicine, University of Alberta, Edmonton, AB, Canada, 2Augurex Life Sciences Corp, North Vancouver, BC, Canada

    Background/Purpose: Serum 14-3-3η is an RA diagnostic marker and higher levels are associated with joint damage and more severe disease. Mechanistically, 14-3-3η upregulates factors involved…
  • Abstract Number: 1296 • 2013 ACR/ARHP Annual Meeting

    Deletion Of RBP-J In a Murine Model Of Inflammatory Arthritis Reveals Pro-Inflammatory Cytokine Expression and Immunophenotypic Differences

    Soumya D. Chakravarty1, Karmen Au2, Lionel B. Ivashkiv3 and Xiaoyu Hu4, 1Rheumatology, Hospital for Special Surgery, New York, NY, 2Hospital for Special Surgery, New York, NY, 3Arthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY, 4Arthritis Tissue Degeneration Program, Hospital for Special Surgery, New York, NY

    Background/Purpose: RBP-J, a DNA-binding protein, serves as the central transcriptional regulator of the Notch signaling pathway. Prior in vitro work has demonstrated that RBP-J plays…
  • Abstract Number: 1297 • 2013 ACR/ARHP Annual Meeting

    Human IL-1alpha Conditional Transgenic Mice Mimic Autoinflammatory Syndromes In Human

    Hiroya Kanagawa1, Yasuo Niki2, Yoshiaki Toyama3 and Takeshi Miyamoto4, 1Department of Orthopaedic Surgery, Keio University, Shinjuku-ku, Tokyo, Japan, 2Orthopaedic Surgery, Department of Orthopaedic Surgery, Keio University, Tokyo, Japan, 3Department of Orthopaedic Surgery, Keio University School of Medicine, Tokyo, Japan, 4Department of Orthopaedic Surgery, Keio University, Shinjuku-ku,Tokyo, Japan

    Background/Purpose: Recently, IL-1 is implicated in the pathogenesis of autoinflammatory syndrome, which characterized by rash, fever, systemic polyarthritis and neurological comorbidity. Recently, IL-1 becomes noticed…
  • Abstract Number: 1299 • 2013 ACR/ARHP Annual Meeting

    PTEN Controls Osteoclastogenesis and Inflammatory Bone Destruction In a TNF-Driven Model Of Arthritis

    Stephan Blueml1, Gernot Schabbauer2, Antonia Puchner3, Victoria Saferding4, Emine Sahin2, Julia Brunner5, Tobias Lohmeyer5, Josef S. Smolen6 and Kurt Redlich7, 1Division of Rheumatology, Medical University of Vienna, Vienna, Austria, 2Vascular Biology and Thrombosis research, Medical University Vienna, Vienna, Austria, 3Department of Rheumatology, Medical University of Vienna, Vienna, Austria, 4Rheumatology, Medical University of Vienna, Vienna, Austria, 5Medical University Vienna, Vienna, Austria, 6Medical University of Vienna, Vienna, Austria, 7Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria

    Background/Purpose: Local bone destruction in inflammatory arthritides in humans such as rheumatoid arthritis is a serious health burden and the major cause of disability and…
  • Abstract Number: 1300 • 2013 ACR/ARHP Annual Meeting

    The Role Of Celastrol On Osteoclastogenesis and Bone Erosion In Collagen-Induced Arthritis

    Ke Gan1,2, Wenfeng Tan3, Miaojia Zhang3, Xiaoke Feng4 and Lingxiao Xu3, 1Rheumatology Department, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China, 2Nanjing University of Chinese Medicine, nanjing, China, 3Department of Rheumatology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, CHINA., Nanjing, China, 4Rheumatology, the First Affiliated Hospital of Nanjing Medical University, China, Nanjing, China

    The Role of Celastrol on Osteoclastogenesis and Bone Erosion in Collagen-Induced ArthritisBackground/Purpose: Celastrus and its extract have been proven effective for treatment Rheumatoid arthritis (RA).…
  • Abstract Number: 1301 • 2013 ACR/ARHP Annual Meeting

    The Tumor Necrosis Factor Stimulated Gene-6 Promoter Reporter Can Monitor The Disease Activity In Rheumatoid Arthritis

    Mathijs G.A. Broeren1, Eline A. Vermeij1, Onno J. Arntz2, Miranda B. Bennink1, Emma Sterken1, Calin Popa2, Tim L. Jansen3, Wim B. van den Berg4 and Fons A.J. Van de Loo5, 1Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 2Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 3Rheumatology, Radboud UMC, Nijmegen, Netherlands, 4Experimental Rheumatology (272), Radboud university medical center, Nijmegen, Netherlands, 5Rheumatology Research and Advanced Therapeutics, Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands

    Background/Purpose: An important step in the optimal personalized treatment of rheumatoid arthritis (RA) patients, is the accurate assessment of disease activity, disease progression and therapy…
  • Abstract Number: 1303 • 2013 ACR/ARHP Annual Meeting

    Variations In Disease Activity and Therapeutic Management Of Rheumatoid Arthritis In Different International Regions: A Comparison Of Data From The Corrona International and Corrona United States Registries

    Dimitrios A. Pappas1, Kathy Lampl2, Joel M. Kremer3, Sebastião C. Radominski4, Janos Gal5, Fredrik Nyberg6, Anand N. Malaviya7, Aimée Whitworth8, Oscar Luis Rillo9, Allan Gibofsky10, Tatiana Popkova11, Meilien Ho12, Ieda Laurindo13, George W. Reed8, Eduardo Mario Kerzberg14, Laura Horne15, Roman Záhora16, Katherine C. Saunders17, Bernado Pons-Estel18, Alina U. Onofrei19 and Jeffrey D. Greenberg20, 1Columbia University, New York, NY, 2AstraZeneca R&D Wilmington, Wilmington, DE, 3Center for Rheumatology, Albany Medical College, Albany, NY, 4Universidade Federal do Paraná, Curitiba, Brazil, 5Rheumatology, County Hospital, Kecskemet, Hungary, 6AstraZeneca R&D, Mölndal, Sweden, 7Rheumatology, Consultant Rheumatologist, ISIC Superspeciality Hospital, New Delhi-11007-, India, 8CORRONA, Inc., Southborough, MA, 9Hospital Tornú, Capital Federal, Argentina, 10Medicine and Public Health, Hospital for Special Surgery, New York, NY, 11Research Institute of Rheumatology -Russian Academy of Medical Science, Moscow, Russia, 12AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, 13Rheumatology, Universidade de São Paulo, São Paulo, Brazil, 14Rheumatology, J. M. Ramos Mejía Hospital, School of Medicine, University of Buenos Aires, Buenos Aires, Argentina, 15AstraZeneca, Wilmington, DE, 16Revmatologická ambulance, Terezin, Czech Republic, 17Corrona, LLC., Southborough, MA, 18Hospital Provincial de Rosario, Rosario, Argentina, 19University of Massachusetts Medical School, Worcester, MA, 20Rheumatology, NYU Hospital for Joint Diseases, New York, NY

    Background/Purpose: The CORRONA International (C.Intl) rheumatoid arthritis (RA) registry is the first multinational RA registry uniformly collecting baseline and longitudinal data.  We explored variations in…
  • Abstract Number: 1304 • 2013 ACR/ARHP Annual Meeting

    Anti-Carbamylated Antibody Positivity Is Associated With More Severe Radiological Progression In Patients With Recent Onset ACPA Negative Rheumatoid Arthritis: Results From The Norfolk Arthritis Register (NOAR)

    Jenny H. Humphreys1, Suzanne M. Verstappen1, Kimme L. Hyrich2, Tarnya Marshall3, Anne Barton4,5, René E.M. Toes6, Leendert A. Trouw6 and Deborah P. Symmons4,7, 1Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, 2Arthritis Research UK Epidemiology Unit, Manchester Academic Health Sciences Centre, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, 3Rheumatology, Norfolk and Norwich University Hospitals Trust, Norwich, United Kingdom, 4Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, 5NIHR Manchester Musculoskeletal BRU, Central Manchester Foundation Trust and University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, 6Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 7NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom

    Background/Purpose: Autoantibodies against carbamylated proteins (anti-CarP) have been associated with more severe radiological damage in patients with rheumatoid arthritis (RA), including in a small subgroup…
  • Abstract Number: 1305 • 2013 ACR/ARHP Annual Meeting

    Clinical Joint Involvement Is Decisive For Radiographic Progression

    Miriam Gärtner1, Farideh Alasti2, Gabriela Supp1, Josef S. Smolen3 and Daniel Aletaha1, 1Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, 2Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, 3Department of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria

    Background/Purpose: Today’s therapeutic targets in rheumatoid arthritis (RA) are remission or low disease activity, but it was shown that joint damage may continue to progress…
  • Abstract Number: 1306 • 2013 ACR/ARHP Annual Meeting

    Do Sustained Clinical Remission and Sustained Low Disease Activity Equally Predict Functional Status In Early Rheumatoid Arthritis?

    Bindee Kuriya1, Juan Xiong2, Gilles Boire3, Boulos Haraoui4, Carol A. Hitchon5, Janet E. Pope6, J. Carter Thorne7, Diane Tin8, Edward C. Keystone9, Cheryl Barnabe10, Pooneh Akhavan11 and Vivian P. Bykerk12, 1Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 2Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 3Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, 4Rheumatology, Institut de Rhumatologie de Montréal, Montreal, QC, Canada, 5University of Manitoba, Winnipeg, MB, Canada, 6Rheumatology, St Joseph Health Centre, London, ON, Canada, 7Southlake Regional Health Centre, Newmarket, ON, Canada, 8The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, 9Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 10Medicine, Community Health Sciences, University of Calgary, Calgary, AB, Canada, 11Medicine, Early Rheumatoid Arthritis Program, Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, 12Divison of Rheumatology, Hospital for Special Surgery, New York, NY

    Background/Purpose:   Sustained clinical remission (REM) is the therapeutic goal in rheumatoid arthritis (RA) but low disease activity (LDA) may be acceptable.  Little is known…
  • Abstract Number: 1307 • 2013 ACR/ARHP Annual Meeting

    Synovial Subset–Derived Baseline Serum Biomarkers Segregate Rheumatoid Arthritis Patients Into Subgroups With Distinct Serum Protein and Clinical Characteristics

    A. Francesca Setiadi, Nicholas Lewin-Koh, Sarah Kummerfeld, David F. Choy, Cécile T.J. Holweg, Sally Fischer, An Song and Michael J. Townsend, Genentech, South San Francisco, CA

    Background/Purpose: Rheumatoid arthritis (RA) is a heterogeneous disease. Predictive biomarkers have the potential to enhance treatment effectiveness by enabling identification of likely responders to a…
  • Abstract Number: 1308 • 2013 ACR/ARHP Annual Meeting

    Low Accuracy Of Radiograph Reports In Identifying Patients With Rheumatoid Arthritis In The Veterans Affairs Rheumatoid Arthritis Registry

    Maria P. Martes1, Alan R. Erickson2, Ted R. Mikuls2 and Grant W. Cannon3, 1Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, 2Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, 3Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT

      Background/Purpose:   The accurate interpretation of hand radiographs is critical in the diagnosis and management of rheumatoid arthritis (RA) patients.  This project determined first,…
  • Abstract Number: 1309 • 2013 ACR/ARHP Annual Meeting

    Prognosis Of Seronegative Patients In a Large Prospective Cohort Of Patients With Early Inflammatory Arthritis

    Lillian J. Barra1, Janet E. Pope2, Boulos Haraoui3, Carol A. Hitchon4, J. Carter Thorne5, Edward C. Keystone6,7, Diane Tin8, Gilles Boire9 and Vivian P. Bykerk10, 1Medicine, Division of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, 2Medicine, Divsion of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, 3Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, 4Rheumatology, University of Manitoba, Winnipeg, MB, Canada, 5Southlake Regional Health Centre, Newmarket, ON, Canada, 6Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 7Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, University of Toronto, Toronto, ON, Canada, 8The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, 9Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, 10Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY

    Background/Purpose: Rheumatoid Factor (RF) and anti-Cyclic Citrullinated Peptide (anti-CCP) are believed to be associated with more severe clinical outcomes; however, studies in Early Inflammatory Arthritis…
  • Abstract Number: 1310 • 2013 ACR/ARHP Annual Meeting

    Evaluation Of The Japanese Patients With Rheumatoid Arthritis (RA) Of Rapid Radiographic Progression (RRP) Treated With Synthetic Disease Modifying Anti-Rheumatic Drugs (DMARDs) In Daily Practice: A Large-Scale Prospective Longitudinal Cohort Study (an interim report of Apple Survey)

    Akitomo Okada1, Atsushi Kawakami2, Takaaki Fukuda3, Toshihiko Hidaka4, Tomonori Ishii5, Yukitaka Ueki6, Takao Kodera7, Munetoshi Nakashima1, Yuichi Takahashi8, Seiyo Honda9, Yoshiro Horai2, Tomohiro Koga10, Mami Tamai11, Kiyoshi Aoyagi12, Ryu Watanabe5, Hiroshi Okuno13 and Katsumi Eguchi14, 1Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, 2Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 3Center for Rheumatic Diseases, Kurume University Medical Center, Kurume, Japan, 4Zenjinkai Shimin-No-Mori Hospital, Miyazaki, Japan, 5Department of Hematology and Rheumatology, Tohoku University, Sendai, Japan, 6Sasebo Chuo Hospital, Sasebo, Japan, 7Tohoku Kosei Nenkin Hospital, Sendai, Japan, 8Yu Family Clinic, Sendai, Japan, 9Kurume University School of Medicene, Kurume, Japan, 10Departments of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 11Center for Health & Community Medicine, Nagasaki University, Nagasaki, Japan, 12Department of Public Health, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 13Tohoku University Hospital, Sendai, Japan, 14Sasebo City General Hospital, Sasebo, Nagasaki, Japan

    Background/Purpose: Disease modifying anti-rheumatic drugs (DMARDs) are known to inhibit radiographic progression in patients with rheumatoid arthritis (RA). However, there has been few epidemiological report…
  • « Previous Page
  • 1
  • …
  • 2161
  • 2162
  • 2163
  • 2164
  • 2165
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology